

Pharmacology and Therapeutics Advisory Committee

Objective advice to Pharmac

www.pharmac.govt.nz

Pharmacology and Therapeutics Advisory Committee Provisional Recommendations 14 August 2026

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.

[More information about provisional recommendations is on Pharmac's website](#)

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
Canakinumab for children and adolescents living with systemic juvenile idiopathic arthritis/Still's disease, as a first line biologic treatment, subject to Special Authority criteria	Medium
Canakinumab for adults living with Still's disease, as a first line biologic treatment, subject to Special Authority criteria	Low
Inclisiran for people living with atherosclerotic cardiovascular disease (ASCVD) who are at high risk, subject to Special Authority criteria	High
Faricimab for people living with macular oedema secondary to retinal vein occlusion, as a second-line anti-VEGF treatment, subject to Special Authority criteria	High
ElementGold Plus+ and ElementGold Plus+ Vegan for people with the currently funded conditions requiring specialised nutritional support, subject to Special Authority criteria	Cost Neutral**
ElementGold Plus+ Vegan for people with the currently funded conditions requiring specialised nutritional support and severe documented allergy to dairy, subject to Special Authority criteria	Low

**Cost Neutral – The Committee has recommended this application be funded if the cost is neutral to the provision of the currently funded medicine(s), including the related health system costs

[More information about the agenda items considered at the recent Pharmacology and Therapeutics Advisory Committee meeting can be found on the Pharmac website](#)

Released 10 September 2026